GlassScriptPhysician profile
James Kyle Horton
NPI 1750321998
$73,146.74
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $21K · 2021: $17K · 2022: $1,251 · 2023: $670 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $46,505.49 | 2019-2023 | Wegovy |
| Sanofi-Aventis U.S. LLC | $19,369.76 | 2019-2023 | |
| Lilly USA, LLC | $684.27 | 2019-2023 | Mounjaro, Jardiance, Humulin |
| Astrazeneca Pharmaceuticals LP | $611.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.67 | 2019-2023 | Synjardy, Tradjenta, Jardiance |
| Abbvie INC. | $493.32 | 2019-2023 | |
| Corcept Therapeutics | $463.85 | 2019-2022 | |
| Dexcom, INC. | $385.76 | 2019-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $360.84 | 2019-2024 | Omnipod |
| Amarin Pharma, INC. | $339.25 | 2019-2022 | |
| Antares Pharma, INC. | $315.53 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Amneal Pharmaceuticals LLC | $268.48 | 2019-2022 | |
| Horizon Therapeutics Plc | $228.59 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $208.05 | 2020-2022 | |
| Amgen INC. | $203.26 | 2019-2023 | Repatha, Evenity, Prolia |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Horton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.